Program
brensocatib
Also written as “Brensocatib”, “Brensocatib 10 mg” and “Brensocatib 25 mg”.
Its studies are mostly in Bronchiectasis · Nasal Polyps · Hidradenitis Suppurativa · Cystic Fibrosis · Renal Insufficiency, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Insmed | 151 open or running | phase 3since Oct 14, 2020 | Jul 11, 2017 | Nov 25, 2026phase 1 · NCT07859007 |
| AstraZeneca | 20 open or running | phase 1since Nov 3, 2014 | Nov 3, 2014 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Nov 3, 2014.
- Jul 11, 2017Insmed's first study: phase 2 study in BronchiectasisNew to InsmedInsmed · NCT03218917 · 256 enrolled · United States, Australia, Belgium and more
- Oct 14, 2020Phase 3 study in Non-Cystic Fibrosis BronchiectasisInsmed · NCT04594369 · 1,767 enrolled · United States, Argentina, Australia and more
- Oct 14, 2021Phase 2 study in Cystic FibrosisInsmed · NCT05090904 · 29 enrolled · United States
- Apr 26, 2022Phase 1 study in Healthy VolunteerInsmed · NCT05355935 · 48 enrolled · United States
- Aug 24, 2022Phase 1 study in Hepatic ImpairmentInsmed · NCT05517525 · 30 enrolled · United States
- Dec 7, 20222 phase 1 studiesInsmed · NCT05652257, NCT05673603
- Apr 12, 2023Phase 1 study in Healthy VolunteersInsmed · NCT05826574 · 32 enrolled · United States
- Jun 22, 2023Phase 1 study in Healthy VolunteersInsmed · NCT05927597 · 82 enrolled · United States
- Jul 19, 2023Phase 1 study in Healthy VolunteersInsmed · NCT05965570 · 22 enrolled · United States
- Aug 22, 2023Phase 2 study in Chronic Rhinosinusitis Without Nasal PolypsInsmed · NCT06013241 · 288 enrolled · United States, Argentina, Australia and more
- Dec 12, 2023Phase 1 study in Healthy VolunteersInsmed · NCT06178783 · 20 enrolled · United States
- Mar 27, 2024Phase 1 study in Healthy ParticipantsInsmed · NCT06344728 · 24 enrolled · United States
- Nov 11, 2024Phase 2 study in Hidradenitis SuppurativaInsmed · NCT06685835 · 214 enrolled · United States, Australia, Bulgaria and more
- Sep 29, 2026Phase 1 study in Healthy VolunteersInsmed · NCT07859007 · 26 planned
Ahead
- Nov 25, 2026Primary completion: phase 1 study in Healthy VolunteersInsmed · NCT07859007
TargetBeta
“An orally bioavailable, small molecule, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), ”NCIt, by rule
“Dipeptidyl peptidase I inhibitor”ChEMBL 37, by rule
Other programs on CTSC
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| verducatib | Boehringer Ingelheim | phase 3 | 21 |
| RSS0343 | Jiangsu HengRui Medicine | phase 2 | 4 |
Studies
All 17 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07859007Healthy Volunteers | 1 | Not yet recruiting | Insmed | Nov 25, 2026 | 26 |
| NCT06685835Hidradenitis Suppurativa · United States, Australia, Bulgaria and more | 2 | Terminated | Insmed | Feb 12, 2026 | 214 |
| NCT06344728Healthy Participants · United States | 1 | Completed | Insmed | May 24, 2024 | 24 |
| NCT06178783Healthy Volunteers · United States | 1 | Completed | Insmed | Jan 4, 2024 | 20 |
| NCT06013241Chronic Rhinosinusitis Without Nasal Polyps · United States, Argentina, Australia and more | 2 | Completed | Insmed | Sep 30, 2025 | 288 |
| NCT05965570Healthy Volunteers · United States | 1 | Completed | Insmed | Sep 22, 2023 | 22 |
| NCT05927597Healthy Volunteers · United States | 1 | Completed | Insmed | Aug 1, 2019 | 82 |
| NCT05826574Healthy Volunteers · United States | 1 | Completed | Insmed | Jul 16, 2023 | 32 |
| NCT05673603Renal Insufficiency · United States | 1 | Completed | Insmed | Feb 14, 2023 | 28 |
| NCT05652257Healthy Volunteers · United States | 1 | Completed | Insmed | Sep 14, 2021 | 7 |
| NCT05517525Hepatic Impairment · United States | 1 | Completed | Insmed | Jun 1, 2023 | 30 |
| NCT05355935Healthy Volunteer · United States | 1 | Completed | Insmed | Oct 7, 2022 | 48 |
| NCT05090904Cystic Fibrosis · United States | 2 | Completed | Insmed | Nov 1, 2022 | 29 |
| NCT04594369Non-Cystic Fibrosis Bronchiectasis · United States, Argentina, Australia and more | 3 | Completed | Insmed | Oct 28, 2024 | 1,767 |
| NCT03218917Bronchiectasis · United States, Australia, Belgium and more | 2 | Completed | Insmed | Dec 12, 2019 | 256 |
| NCT02653872Healthy Subjects · United Kingdom | 1 | Completed | AstraZeneca | Apr 13, 2016 | 15 |
| NCT02303574Safety, Pharmacokinetics, Pharmacodynamics, Food Effect · United Kingdom | 1 | Completed | AstraZeneca | Aug 3, 2016 | 89 |
How it is read
Names in the registry
- “Brensocatib”, 10 entries
- “Brensocatib 10 mg”, 2 entries
- “Brensocatib 25 mg”, 2 entries
- “Brensocatib Oral Solution”, 1 entry
- “Brensocatib Oral Tablet”, 1 entry
Codes read as this program: AZD7986.
Conditions, from the studies’ own filings
- Bronchiectasis, 2 studies
- Nasal Polyps, 1 study
- Hidradenitis Suppurativa, 1 study
- Cystic Fibrosis, 1 study
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.